KEAP1 and Parkinson disease: These findings were corroborated in the MPTP-induced PD mouse model, where LRRK2 inhibition effectively attenuated microglial activation, reduced dopaminergic neuronal loss, and enhanced the activity of the p62-Keap1-Nrf2 pathway, leading to improved motor function.